Literature DB >> 18176387

[Which definition to use when defining reversibility of airway obstruction?].

H Ben Saad1, R Ben Attia Saafi, S Rouatbi, S Ben Mdella, A Garrouche, A Hadj Mtir, I Harrabi, Z Tabka, A Zbidi.   

Abstract

INTRODUCTION: There is no clear consensus about what constitutes reversibility of airway obstruction. European Respiratory Society (ERS): Increase in FEV1 and/or FVC>12% of their theoretical value and>0.2l. British Thoracic Society: FEV1>15% of initial value and FEV1>0.2l. Global Initiative for Chronic Obstructive Lung Disease: Increase in FEV1>12% and>0.2l. Australia and New Zealand Thoracic Society: Increase in FEV1 >15%. American Thoracic Society/ERS: Increase in FEV1>12% and>0.2l or increase in FVC>12% and 0.2l. Our principal objective was to determine the percentage of patients with COPD (n=62) who were significant responders to the reversibility test according to the 5 recommendations.
METHODS: Plethysmography was performed before and 15 minutes after inhalation of 400 micrograms of a short acting bronchodilator (BD). COPD is defined as a FEV1/FVC post BD<0.7.
RESULTS: The percentage of responders varied from 24% to 50% depending on the recommendations used.
CONCLUSION: Reversibility of airway obstruction is recommendation dependent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18176387     DOI: 10.1016/s0761-8425(07)74260-2

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

1.  Pulmonary functions of narghile smokers compared to cigarette smokers: a case-control study.

Authors:  Helmi Ben Saad; Mehdi Khemiss; Saida Nhari; Mejda Ben Essghaier; Sonia Rouatbi
Journal:  Libyan J Med       Date:  2013-12-30       Impact factor: 1.743

2.  Determining the optimal time to assess the reversibility of airway obstruction.

Authors:  Jamel El Ghoul; Maher Abouda; Meriem Triki; Abdessalem Ghourabi; Ridha Charfi
Journal:  Lung India       Date:  2019 Mar-Apr

3.  Defining obstructive ventilatory defect in 2015.

Authors:  Zied Affes; Salaheddine Rekik; Helmi Ben Saad
Journal:  Libyan J Med       Date:  2015-10-08       Impact factor: 1.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.